유리 (1) 30 ml 세균성 물 자격을 갖춘 주문이 있습니다$ 500 USD.
(캡슐 제품, 미용 펩티드, 프로모션 코드 및 배송 제외)
Vilon은 강력한 면역 조절제 및 노화 방지 바이오 레게 제제 펩티드로, 그 이점을 뒷받침하는 충분한 연구가 있습니다. Vilon이 암 발병 및 진행의 위험을 예방/감소시키는 데 도움이 될 수 있다는 높은 수준의 증거도 있습니다. 흥미롭게도, 연구에 따르면 Vilon은 초기에 일관되고 일관된 저용량으로 더 나은 노화 방지 효과를 제공하는 것으로 보입니다. 이러한 결과는 더 나은 노화 방지 연구의 문을 열고 과학자들이 후성 유전 학적 규제가 장수에서 중요한 역할을하는 방법을 더 잘 이해하는 데 도움이 될 수 있습니다.
제품 사용 :이 제품은 연구 화학 물질로만 의도 된 것입니다.이 명칭은 시험 관내 시험 및 실험실 실험에만 연구 화학 물질을 엄격하게 사용할 수있게한다. 이 웹 사이트에서 제공되는 모든 제품 정보는 교육 목적으로 만 사용됩니다. 인간이나 동물에 어떤 종류의 신체적으로 소개되는 것은 법에 의해 엄격히 금지되어 있습니다. 이 제품은 라이센스가 부여 된 자격을 갖춘 전문가 만 처리해야합니다. 이 제품은 약물, 음식 또는 화장품이 아니며 약물, 음식 또는 화장품으로 잘못 브랜드화되거나 잘못 사용되거나 오해가되지 않을 수 있습니다.
사악한
길이가 2 개의 아미노산에서, Vilon은 생물학적 활성을 갖는 것으로 알려진 가장 짧은 펩티드이다. 연구에 따르면 Vilon은 강력한 노화 방지 효과를 가지고 있으며 면역 기능의 강력한 조절제라고합니다. Vilon이 혈관 시스템을 조절하는 데 도움이되고 지혈을 촉진한다는 좋은 증거도 있습니다. Vilon은 자발적인 종양의 발생률과 성장을 감소시키는 것으로 나타 났지만, 암 치료에서 보조제로서의 역할 (예방과는 달리)은 의문의 여지가 있습니다. 전반적으로, Vilon은 Vladimir Anisimov 박사와 같은 몇 가지 옹호자들을 보유하고 있으며, 그는 펩티드가 유용한 geroprotective gent라고 생각합니다.
Vilon과 면역계
Research out of Russia indicates that Vilon is a potent regulator of chromatin structure. One study found that Vilon:
• induces unrolling of chromatin,
• activates synthetic processes via reactivation of ribosomal genes in the unrolled chromatin,
• releases repressed genes, and
• does not cause decondensation of pericentromeric structural chromatin[1].nduces unrolling of chromatin,
The net result of the changes that Vilon causes to DNA is reactivation of genes that are otherwise silenced. In general, chromatin is found in either the wound (heterochromatin) or unwound (euchromatin) states. Heterochromatin cannot be accessed by the apparatus that turns genes into proteins and thus functional components of the cell. Genes in these regions of DNA are simply unavailable for protein production.
In general, chromatin helps to regulate which genes are available for transcription and is thus one way that different-cells can have different functions or that the same cells can have different functions over time. Unfortunately, chromatin condensation is also something that occurs as a result of aging and senescence and is at least one reason why our cells and tissues lose function as we get older.
Similar to its activity in lymphocytes, Vilon has been shown to activate interluekin-2 signaling in cells of the spleen[3]. Interleukin-2 is important in coordinating the immune response to microbial infection and helps to prevent autoimmune reactions. By activating lymphocytes and splenocytes while boosting natural protection against autoimmune reactions, Vilon restores the immune system to a more active state and may even be useful in developing treatments for autoimmune diseases.
Adding to its ability to prevent autoimmune reactions is the role of Vilon in the thymus. Research in thymus cultures shows that Vilon increases the proliferation of CD5 T-cells. CD5 is a marker of mature T-helper cells as well as cytotoxic CD8 T-cells. The former helps to regulate the immune system and prevent autoimmune reactions, while the latter is one of the most potent anti-microbial cells in the body[4].
Interestingly, Vilon appears to only reactivate immune functions via genes that have been silenced by changes in chromatin. It does not appear to activate genes that would naturally be silent in the cells it affects. In other words, Vilon does not turn lymphocytes into neurons by activating genes that would normally not be active in healthy lymphocytes. Instead, the peptide appears to boost activity in the immune system while simultaneously helping to prevent autoimmune reactions.
Vilon과 암
As pointed out above, Vilon helps to reduce the incidence of cancer in mouse models, which is at least one way in which it prolongs average lifespan. Additional research shows that Vilon not only prevents tumors from forming, but inhibits their growth after they are present[5]. This suggests that Vilon may be both an effective chemotherapeutic in its own right, as well as a potential additive to existing cancer treatments. In the future, Vilon may be a standard addition to everything from chemotherapy to radiation treatment and surgery.
At least one study, out of Russia, contradicts the claim that Vilon may be a useful adjuvant to chemotherapy. The works shows that the combination of Vilon and platinum-based chemotherapeutic agents is problematic rather than synergistic[6]. Unfortunately, this study used only one specific type of chemotherapy and was limited in scope, so the results cannot be generalized. It remains to be seen if Vilon is only effective against cancer on its own or if the peptide can be added to other treatment regimens to boost results.
Vilon과 노화
Research in mice shows that subcutaneous administration of Vilon increases physical activity and endurance while helping to reduce the risk of cancer. These two effects resulted in longer lifespan in the treated mice, suggesting that Vilon may be a legitimate anti-aging peptide[7]. This is especially encouraging given that it produced no adverse effects in the mice following long-term administration.
Interestingly, the research shows that the earlier Vilon is administered, the greater its effects seem to be. In other words, giving Vilon to young mice enhances lifespan more than if Vilon is not administered until the mice are much older. This same effect was seen in early studies looking at crude thymic and pineal extracts given to mice to slow down aging[8]. The speculation is that Vilon and similar peptides, when administered late in life, can reverse senescence in existing cells but can obviously do nothing for cells that have already been eliminated through apoptosis. By administering Vilon 20mg early in life, cells get the greatest amount of protection and so turnover is slowed down. The result is that more cells stay healthy for longer periods of time, slowing the need to replace them and preserving limited stem cell lines.
Vilon’s anti-aging effects seem to extend to GI function as well, where the peptide has been shown to improve the activity of certain enzymes in the Gi tracts of older mice. The peptide also appears to improve barrier function, thus reducing the incidence of leaky gut, enhancing disease resistance, and improving the overall health of the GI tract in older mice[9]. Research shows that Vilon thereby helps to improve glucose and glycine absorption in the small intestine of older rats[10]. These features of Vilon may help to maintain nutrient extraction with age, thereby improving overall well-being and perhaps enhancing longevity.
Dr. Vladimir N. Anisimov, who has been researching aging and cancer development since the 1970s, points out that the thymus is one of two glands (the other being the pineal gland) that plays an important role in regulating aging. The healthier the thymus is, the healthier we are as individuals. Of course, Vilon is a thymic peptide and affects cells, like lymphocytes, that are produced in and mature in the thymus. Dr. Anisimov is a staunch advocate for using peptide bioregulators in the prevention of cancer[11]. He is a close colleague of Dr. Vladimir Khavinson.
심장과 신장의 빌론
The effect of Vilon on the vasculature has been less well studied, but there is some work to suggest that it may have a beneficial effect. Research in mice shows that Vilon changes the expression of more than 36 different genes within the heart. When combined with Epithalon, this number jumps to 144 genes[12]. These findings suggest that, at the very least, Vilon has the ability to alter gene expression patterns in the cardiovascular system, a fact that may improve hemodynamic function.
In fact, research in kidneys, highly vascular organs, shows that Vilon decreases concentrations of transforming growth factor-beta(1) and thus the permeability of microvessels. The net result is improved hemostasis during kidney failure, suggesting that Vilon does, in fact, have a beneficial effect on the vascular system[13].
Furthermore, research in elderly patients with diabetes shows that Vilon can help to optimize coagulation by increasing levels of the natural anticoagulants antithrombin III and protein C while also stimulating fibrinolysis[14]. The result is fewer blood clots in a population prone to clotting and the serious consequences that follow. This further supports the idea that Vilon plays an important role in regulating the vascular system.
Vilon 요약
Vilon is a potent immunomodulator and anti-aging peptide with ample research to back its benefit. There are also high levels of evidence that Vilon reduces the risk of cancer development and progression. Interestingly, Vilon appears to provide better anti-aging and anti-cancer effects when administered early in life and at chronic, low doses. These features may help open the door to better anti-aging research and help scientists to better understand how epigenetic regulation plays an important role in longevity.
Vilon exhibits minimal side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. Vilon for sale at
펩티드 전문가인간 소비가 아닌 교육 및 과학 연구로만 제한됩니다. 면허가있는 연구원 인 경우 Vilon 만 구입하십시오.
기사 저자
위의 문헌은 M.D. E. Logan 박사가 연구, 편집 및 조직했습니다. E. Logan 박사는 박사 학위를 취득했습니다.사례 서부 예비 대학교 의과 대학그리고 B.S. 분자 생물학에서.
과학 저널 저자
블라디미르 카빈슨노인과 노인 학회의 유럽 지역 회장, 교수입니다. 회원러시아 및 우크라이나 의학 아카데미; 러시아 피터스 버그 정부의 보건위원회의 주요 노인 학자; 상트 페테르부르크 생물 저지 및 노인학 연구소 소장; Gerontological Society의 부회장러시아 과학 아카데미; ST-Petersburg의 Genorth-Western State Medical University의 Gerontology 및 노인학 의장; 의료 서비스 대령 (USSR, 러시아), 은퇴.펩티드생물 조절제 및 생물 조절 펩티드 요법의 발달. 그는 노화 메커니즘의 조절에서 펩티드의 역할을 연구하고있다. 그의 주요 행동 분야는 새로운 펩티드의 설계, 전임상 및 임상 연구입니다.Geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications.His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002)and “Gerontological aspects of genome peptide regulation” (Karger AG, 2005).Vladimir Khavinson introduced scientific specialty “Gerontology and Geriatrics” in the Russian Federation on the governmental level. Academic Council headed by V. Khavinson has oversighted over 200 Ph.D. and Doctorate theses from many different countries.
Prof. Vladimir Khavinson is being referenced as one of the leading scientists involved in the research and development of Livagen. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between
펩티드 전문가그리고이 의사. 의사를 인용하는 목적은이 펩티드를 연구하는 과학자들이 수행 한 철저한 연구 개발 노력을 인정, 인식 및 인정하는 것입니다. Vladimir Khavinson 교수는 [1] [3] [4] [5] [7] [8] [9] [10] [11] 및 [12]에 참조 된 인용 하에서 나열되어 있습니다.
참조 인용
[1] T. Lezhavaet al., “Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people,”Biogerontology, vol. 5, no. 2, pp. 73–79, 2004, doi: 10.1023/B:BGEN.0000025070.90330.7f.
[2] T. Lezhava, J. Monaselidze, T. Kadotani, N. Dvalishvili, and T. Buadze, “Anti-aging peptide bioregulators induce reactivation of chromatin,”Georgian Med. News, no. 133, pp. 111–115, Apr. 2006.
[3] T. B. Kazakovaet al., “In vitro effect of short peptides on expression of interleukin-2 gene in splenocytes,”Bull. Exp. Biol. Med., vol. 133, no. 6, pp. 614–616, Jun. 2002, doi: 10.1023/a:1020210615148.
[4] N. N. Sevostianovaet al., “Immunomodulating effects of Vilon and its analogue in the culture of human and animal thymus cells,”Bull. Exp. Biol. Med., vol. 154, no. 4, pp. 562–565, Feb. 2013, doi: 10.1007/s10517-013-2000-0.
[5] V. K. Khavinson and V. N. Anisimov, “A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice,”Dokl. Biol. Sci. Proc. Acad. Sci. USSR Biol. Sci. Sect., vol. 372, pp. 261–263, Jun. 2000.
[6] O. P. Barykina, V. V. Iuzhakov, N. I. Chalisova, I. M. Kvetnoĭ, and S. S. Konovalov, “[Combined effect of vilon and cyclophosphane on tumor transplants and lymphoid tissue explants in mice and rats of various age],”Adv. Gerontol. Uspekhi Gerontol., vol. 12, pp. 128–131, 2003.
[7] V. K. Khavinsonet al., “Effect of vilon on biological age and lifespan in mice,”Bull. Exp. Biol. Med., vol. 130, no. 7, pp. 687–690, Jul. 2000, doi: 10.1007/BF02682106.
[8] V. N. Anisimov, A. S. Loktionov, V. K. Khavinson, and V. G. Morozov, “Effect of low-molecular-weight factors of thymus and pineal gland on life span and spontaneous tumour development in female mice of different age,”Mech. Ageing Dev., vol. 49, no. 3, pp. 245–257, Sep. 1989, doi: 10.1016/0047-6374(89)90075-4.
[9] V. K. Khavinson, N. M. Timofeeva, V. V. Malinin, L. A. Gordova, and A. A. Nikitina, “Effect of vilon and epithalon on activity of enzymes in epithelial and subepithelial layers in small intestine of old rats,”Bull. Exp. Biol. Med., vol. 134, no. 6, Art. no. 6, Dec. 2002.
[10 ]V. K. Khavinson, V. V. Egorova, N. M. Timofeeva, V. V. Malinin, L. A. Gordova, and L. V. Gromova, “Effect of Vilon and Epithalon on glucose and glycine absorption in various regions of small intestine in aged rats,”Bull. Exp. Biol. Med., vol. 133, no. 5, pp. 494–496, May 2002, doi: 10.1023/a:1019878224754.
[11] V. N. Anisimov and V. K. Khavinson, “[The use of peptide bioregulators for cancer prevention: results of 35 years of research experience and perspectives],”Vopr. Onkol., vol. 55, no. 3, pp. 291–304, 2009.
[12] S. V. Anisimov, K. R. Bokheler, V. K. Khavinson, and V. N. Anisimov, “Studies of the effects of Vilon and Epithalon on gene expression in mouse heart using DNA-microarray technology,”Bull. Exp. Biol. Med., vol. 133, no. 3, pp. 293–299, Mar. 2002, doi: 10.1023/a:1015859322630.
[13] N. A. Gavrisheva, V. V. Malinin, T. P. Ses, K. L. Kozlov, A. V. Panchenko, and A. Y. Titkov, “Effect of peptide Vilon on the content of transforming growth factor-beta and permeability of microvessels during experimental chronic renal failure,”Bull. Exp. Biol. Med., vol. 139, no. 1, pp. 24–26, Jan. 2005, doi: 10.1007/s10517-005-0202-9.
[14] B. I. Kuznik, N. V. Isakova, N. N. Kliuchereva, N. V. Maleeva, and I. S. Pinelis, “[Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus],”Adv. Gerontol. Uspekhi Gerontol., vol. 20, no. 2, pp. 106–115, 2007.이 웹 사이트에 제공된 모든 기사 및 제품 정보는 정보 및 교육 목적만을위한 것입니다.이 웹 사이트에서 제공되는 제품은 투명한 연구를 위해 제공됩니다. 내역 연구 (라틴어 : 유리)는 신체 외부에서 수행됩니다. 이 제품은 의약품이나 약물이 아니며 FDA에 의해 의학적 상태, 질병 또는 질병을 예방, 치료 또는 치료하기 위해 승인되지 않았습니다. 인간이나 동물에 어떤 종류의 신체적으로 소개되는 것은 법에 의해 엄격히 금지되어 있습니다.
